Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Otsuka Snags APAC Rights to 4DMT’s AMD Gene Therapy
November 4, 2025
- Lenvima-Keytruda Combo’s Liver Cancer Trial Halted after OS Miss
October 31, 2025
- Boehringer Bags Rights to Kyowa Kirin’s Preclinical Autoimmune Program
October 31, 2025
- Espha’s Velcade AG Wins Approval for Mantle Cell Lymphoma
October 31, 2025
- MSD Files for Keytruda Label Expansion in Ovarian Cancer
October 31, 2025
- Astellas Beats H1 Forecast on Strategic Product Growth, Cost Controls
October 31, 2025
- Vyvanse Generics Drag Takeda Earnings; FY2025 Outlook Trimmed
October 31, 2025
- Pfizer Resumes Supply of Smoking Cessation Pill Champix after 4 Years
October 31, 2025
- Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
October 31, 2025
- Leqembi’s April-September Sales at 41.1 Billion Yen: Eisai
October 31, 2025
- TMS Founder Sees “Ray of Hope” in Novel Stroke Drug TMS-007
October 31, 2025
- Jardiance Dominates September Detailing Rankings with Five Wins: Intage
October 31, 2025
- MSD Launches 21-Valent Pneumococcal Vaccine Capvaxive in Japan
October 30, 2025
- AbbVie Files Skyrizi for Pediatric Dosage in Japan
October 30, 2025
- LifeScan Japan Taps AI to Fast-Track Sales Force Development, Draws Interest from Pharma
October 29, 2025
- J-TEC, AlliedCel Ink Service Contract for T-Cell Therapy Production
October 29, 2025
- Japan Gives Orphan Tags for Kyowa Kirin’s Gene Therapy, Cuorips’ Cell Sheet
October 29, 2025
- NEC Crafts Data Platform to Advance Personalized Cancer Vaccine Program
October 28, 2025
- Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
October 28, 2025
- Novo to End Sales of Victoza in Japan, Fourth GLP-1 to Exit Market
October 28, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…